Compare Ascendis Pharma A/S (ASND) vs American Express Co (AXP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs American Express Co — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while American Express Co trades at $354.27 (market cap $239.21B). The key difference: American Express Co is far larger — about 13.5× Ascendis Pharma A/S's market cap, and American Express Co pays a 1.08% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | AXP | |
|---|---|---|
Market Cap | $17.74B | $239.21B |
Sector | Health | Financials |
52-Week High | $277.18 | $384.82 |
52-Week Low | $163.32 | $292.27 |
Enterprise Value | $18.11B | — |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
American Express (AXP) trades at $350.58, up 1.11% today, with a bullish technical signal and strong fundamentals. Revenue grew to $72.23B in 2025, with net income of $10.83B and a 15.13% margin. Recent earnings beat expectations in Q1 2026, and the company is expanding its premium cardholder perks and AI initiatives, including a new NFL partnership and headquarters development at 2 World Trade Center.
The outlook is positive with a consensus price target of $375.27, implying 7% upside. Risks include economic sensitivity and competitive pressures, but robust consumer spending and innovation in digital payments support growth. Analyst sentiment is mixed with 38.6% buy ratings, highlighting potential for steady gains amid macroeconomic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About American Express Co
American Express Company is a global payment and travel company. The Company's principal products and services are charge and credit payment card products and travel-related services offered to consumers and businesses around the world.
Read more on AXP →
